JW신약

067290KOSDAQ의약품 제조업

60.5 / 100

Reference Date: 2026-07-24

Financial Score23.0 / 40

News Sentiment18.5 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PBR raises overvaluation concerns. Plunged 24.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

JW Shinapharm primarily engages in the manufacturing and sales of pharmaceuticals, building a systematic sales network through joint marketing with JW Chungwa Pharmaceutical. Its subsidiary, JW Crigen, specializes in cell therapy products. In 2024, the company achieved consolidated sales of 93 billion won and an operating profit of 10 billion won. Key products include antifungal medications, dermatological treatments, and internal medicine drugs.

Number of Employees

173people

Average Salary

69.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

8.09Industry Average 11.236.5Point

Lower than industry avg (good)

PBR

2.73Industry Average 0.810.0Point

3.4x industry avg (risky)

ROE

46.53Industry Average 4.017.0Point

11.6x industry avg (excellent)

Debt Ratio

5.17Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲25.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -11.2% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 5Neutral 1Negative 0Average Sentiment Score 74.2

Positive
JW신약, 듀크레이 '케르티올 컨센트레이트 크림' 각질 개선 만족 99...
JW신약의 케르티올 크림이 인플루언서 대상 설문조사에서 각질 개선 효과에 대한 높은 만족도를 보여 긍정적인 시장 반응을 이끌어냈다.
Positive
JW신약, 모발 케어 화장품 뷰티클래스 개최
JW신약의 뷰티클래스 개최로 모발 케어 제품 인지도 향상 및 긍정적인 소비자 반응 기대.
Positive
JW신약, 듀크레이 네옵타이드 엑스퍼트 뷰티클래스 진행
JW신약의 뷰티클래스 개최로 인해 젊은 여성 소비자들의 관심과 신뢰도 상승 예상.

Detailed Momentum

52-week position3.0Point

52w lower range (37%)

Current 1,982Won52-week high 3,10552-week low 1,294

1-month return0.0Point

1m -24.64% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0